Chimeric Therapeutics Ltd (ASX:CHM)’s CHM 1101 glioblastoma abstract has been selected for presentation at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from 2-6 June 2023 in Chicago, Illinois.
The abstract titled ‘Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma’ was selected for presentation from more than 6,500 abstracts submitted.
Chimeric noted that it is pleased that ASCO has selected the abstract for presentation as it highlights the clinical trial design and objectives of the company’s new multi-site Phase 1B clinical trial with CHM 1101 in patients with recurrent or progressive glioblastoma (GBM).
Details of the abstract presentation are as follows:
Section: Central Nervous System Tumors
Abstract #: 418236
Title: Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma
Session Date and Time: 3 June 2023, 1:15 PM-4:15 PM
Phase 1 clinical trial
Last month, Chimeric welcomed the initiation of the fourth dose cohort of City of Hope’s phase 1 clinical trial evaluating the safety and tolerability of Chimeric’s CHM 1101 cell therapy.
The first patient in the fourth dose cohort in the phase 1 clinical trial in recurrent/progressive glioblastoma has received dosing at City of Hope Cancer Center in the US.
This cohort will see patients treated at a total dose of 440 X 106 CHM 1101 (CLTX CAR T cells) through dual routes of intratumoral and intraventricular administration.
Progression to this level follows the successful completion of the third dose cohort without any dose-limiting toxicities in January 2023.